KR0137959B1 - 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물 - Google Patents

2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물

Info

Publication number
KR0137959B1
KR0137959B1 KR1019900700977A KR900700977A KR0137959B1 KR 0137959 B1 KR0137959 B1 KR 0137959B1 KR 1019900700977 A KR1019900700977 A KR 1019900700977A KR 900700977 A KR900700977 A KR 900700977A KR 0137959 B1 KR0137959 B1 KR 0137959B1
Authority
KR
South Korea
Prior art keywords
dipyrrole
chloromethyl
compound
methylbenzo
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019900700977A
Other languages
English (en)
Korean (ko)
Other versions
KR900701801A (ko
Inventor
씨. 켈리 로보트
에이. 아리스토프 폴
Original Assignee
로버트 에이. 아미테이지
디 업존 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이. 아미테이지, 디 업존 캄파니 filed Critical 로버트 에이. 아미테이지
Publication of KR900701801A publication Critical patent/KR900701801A/ko
Application granted granted Critical
Publication of KR0137959B1 publication Critical patent/KR0137959B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Error Detection And Correction (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Artificial Filaments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Amplifiers (AREA)
  • Solid State Image Pick-Up Elements (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Television Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Stereophonic System (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Television Receiver Circuits (AREA)
KR1019900700977A 1988-09-12 1989-08-07 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물 Expired - Fee Related KR0137959B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24335088A 1988-09-12 1988-09-12
US7/243,350 1988-09-12
US07/243,350 1988-09-12
PCT/US1989/003329 WO1990002746A1 (en) 1988-09-12 1989-08-07 Novel cc-1065 analogs having two cpi subunits

Publications (2)

Publication Number Publication Date
KR900701801A KR900701801A (ko) 1990-12-04
KR0137959B1 true KR0137959B1 (ko) 1998-05-15

Family

ID=22918400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700977A Expired - Fee Related KR0137959B1 (ko) 1988-09-12 1989-08-07 2개의 cpi 소단위를 갖는 신규한 cc-1065 유사화합물

Country Status (14)

Country Link
US (1) US5541339A (enExample)
JP (1) JP3380237B2 (enExample)
KR (1) KR0137959B1 (enExample)
AT (1) ATE198335T1 (enExample)
AU (1) AU632288B2 (enExample)
CA (1) CA1340215C (enExample)
DE (1) DE68929275T2 (enExample)
DK (1) DK175458B1 (enExample)
FI (1) FI103668B1 (enExample)
GR (1) GR3035589T3 (enExample)
LV (1) LV12806B (enExample)
NO (1) NO303498B1 (enExample)
TW (1) TW217383B (enExample)
WO (1) WO1990002746A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2076465C (en) * 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
BR0214019A (pt) 2001-11-09 2004-10-13 Boehringer Ingelheim Phamaceut Benzimidazóis úteis como inibidores de proteìna quinase
EP1529046A1 (en) * 2002-08-08 2005-05-11 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
JP2006505571A (ja) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
US20070213374A1 (en) * 2003-07-07 2007-09-13 Merck Patent Gmbh Malonamide Derivatives
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
US7446195B2 (en) * 2005-08-17 2008-11-04 Schering Corporation High affinity thiophene-based and furan-based kinase ligands
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CA2680854C (en) 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
MX2011004625A (es) 2008-11-03 2011-07-20 Syntarga Bv Analogos cc-1065 novedosos y sus conjugados.
CA2956934C (en) 2010-04-21 2019-07-09 Syntarga B.V. Novel conjugates of cc-1065 analogs and bifunctional linkers
WO2014066400A2 (en) 2012-10-22 2014-05-01 Arnold Glazier Methods for the effective treatment of metastatic cancer
DE102013012622A1 (de) * 2013-07-30 2015-02-05 Clariant lnternational Ltd Neue sterisch gehinderte cyclische Amine
AU2015205574B2 (en) 2014-01-10 2019-08-15 Byondis B.V. Method for purifying Cys-linked antibody-drug conjugates
CA2937731C (en) * 2014-01-27 2019-09-24 Pfizer Inc. Bifunctional cytotoxic agents
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
DE102015000124A1 (de) * 2015-01-07 2016-07-07 Clariant International Ltd. Verfahren zur Stabilisierung von Polyamiden
WO2016151432A1 (en) * 2015-03-20 2016-09-29 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4301248A (en) * 1979-12-21 1981-11-17 Bristol-Myers Company Fermentation process for making rachelmycin
US4413132A (en) * 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
GB8528848D0 (en) * 1985-11-22 1985-12-24 Davy Mckee Poole Rolling mills
MX9203200A (es) * 1986-12-19 1992-09-01 Upjohn Co Analogos de cc. 1065 novedosos.

Also Published As

Publication number Publication date
JP3380237B2 (ja) 2003-02-24
LV12806B (lv) 2002-05-20
CA1340215C (en) 1998-12-15
DK41791A (da) 1991-03-08
WO1990002746A1 (en) 1990-03-22
DE68929275D1 (de) 2001-02-01
DK41791D0 (da) 1991-03-08
KR900701801A (ko) 1990-12-04
ATE198335T1 (de) 2001-01-15
TW217383B (enExample) 1993-12-11
NO910958L (no) 1991-05-10
DK175458B1 (da) 2004-11-01
DE68929275T2 (de) 2001-05-23
FI103668B (fi) 1999-08-13
AU4192289A (en) 1990-04-02
JPH04500664A (ja) 1992-02-06
GR3035589T3 (en) 2001-06-29
LV12806A (en) 2002-03-20
US5541339A (en) 1996-07-30
NO910958D0 (no) 1991-03-11
NO303498B1 (no) 1998-07-20
AU632288B2 (en) 1992-12-24
FI103668B1 (fi) 1999-08-13
FI911193A0 (fi) 1991-03-11

Similar Documents

Publication Publication Date Title
US5541339A (en) CC-1065 analogs having two CPI subunits
JP5276582B2 (ja) 抗ウイルス剤としての五環インドール誘導体
CA2381885C (en) Isomeric fused pyrrolocarbazoles and isoindolones
AU2016280236B2 (en) Nrf2 regulators
US7521443B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CA2420592C (en) Fused pyrrolocarbazoles against inflammation
US20070270417A1 (en) Antibacterial Agents
JP2008517986A (ja) 抗ウイルス薬としての四環式インドール誘導体
AU2007253998A1 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AU2007361468A1 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP0359454B1 (en) CC-1065 analogs having two CPI subunits
AU613392B2 (en) Imidazo (1,2-b) pyridazin-2-yl carbamate derivatives
US7795247B2 (en) Tetracyclic indole derivatives as antiviral agents
KR100399704B1 (ko) 축합다환식헤테로환유도체
EP0491814B1 (en) Tetracyclic imidazoquinazoline derivatives, preparation and pharmaceutical compositions
MXPA06007325A (en) Novel fused pyrrolocarbazoles

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20050630

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060214

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060214

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000